Study: Drug given during PCI lowers bleeding risk

10/18/2011 | MedPage Today (free registration)

A trial of more than 8,000 patients led by New York University School of Medicine researchers found bivalirudin administered during PCI saw a decreased bleeding risk compared with the use of heparin or heparin combined with glycoprotein IIb-IIIa inhibitors. Researchers also found no increase in thrombotic or ischemic issues in the 12 months following PCI where bivalirudin was used. The results were published in the journal Circulation: Cardiovascular Interventions.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Chief Executive Officer
UCare Minnesota
Minneapolis, MN
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC